Posterior ocular fibrosis inhibition by antagonizing placental growth factor

A technology of placental growth factor and growth factor, applied in the field of eye treatment, can solve problems such as lack of effect

Inactive Publication Date: 2018-11-09
OXURION NV
View PDF19 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Friedlander (J Clin Invest 2007,117:576-586) summarized the effect of VEGF antagonists on back of eye lack of fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Posterior ocular fibrosis inhibition by antagonizing placental growth factor
  • Posterior ocular fibrosis inhibition by antagonizing placental growth factor
  • Posterior ocular fibrosis inhibition by antagonizing placental growth factor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0141] 1 Introduction

[0142] This study investigated the effect of anti-PlGF antibodies (mouse PLGF inhibitory antibody 5D11D4 or human PlGF inhibitory antibody 16D3, ThromboGenics, Leuven, Belgium) on one or more of neovascularization, inflammation and collagen deposition in a mouse model of CNV. Dose-response potency of PlGF inhibition; and comparing it with equimolar concentrations of anti-VEGF-R2 antibody (DC101, produced by hybridoma cell line ATCC HB-11534), aflibercept ( Bayer), triamcinolone acetonide (TAAC; Bristol-Myers Squibb) was compared with the anti-mouse VEGF antibody B20 (Liang et al. 2006, JBiol Chem 281:951-961). TAAC was used as a reference for inflammation and fibrosis. Based on the activity in the mouse CNV model described by Takata et al. (Takata et al., Sci Rep 2015, 5:9898), a single injection of 1 μL TAAC was chosen as the treatment regimen. The effects of anti-PlGF antibody 5D11D4 and anti-VEGF-R2 antibody DC101 on RGC survival were studied ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to view more

Abstract

The invention is situated in the field of ocular therapies. In particular it refers to antagonists of placental growth factor for interfering with posterior ocular fibrosis.

Description

technical field [0001] The present invention relates to the field of eye therapy. Specifically, it relates to antagonists of placental growth factor for interfering with posterior eye fibrosis. Background technique [0002] The retina of the eye (most of the posterior segment of the eye; the back of the eye) is part of the central nervous system (CNS). As such, the wound-healing response of the retina is similar to that of the brain, which Friedlander termed gliosis (glial cell-mediated fibrosis). This is in contrast to wound-healing responses in non-CNS tissues or organs in general and the anterior segment of the eye (front of the eye), such as the cornea and trabecular meshwork, specifically termed fibrosis (fibroblast-mediated fibrosis) (Friedlander 2007 , J Clin Invest, 117:576-586). [0003] Any type of retinal disease or disorder caused by or accompanied by inflammation and / or neovascularization results in gliosis and fibrous scarring. This gliosis, or fibrosis at ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/22C07K16/28A61P27/02
CPCC07K16/22A61K2039/505A61K2039/507A61K2039/54A61K2039/545C07K2317/24C07K2317/76C07K16/2863A61P27/02A61K45/06A61K2300/00
Inventor 蒂内·范贝尔根巴特·乔恩克斯琼·费恩
Owner OXURION NV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap